Kazia Therapeutics Annual Reports 2023

44 STATEMENT OF CHANGES IN EQUITY For the year ended 30 June 2023 Contributed equity Other contributed equity Foreign currency translation reserve Share based payments reserve Accumulated losses Total equity Consolidated $ $ $ $ $ $ Balance at 1 July 2021 (as originally reported) 80,290,062 464,000 (453,320) 1,753,886 (44,203,909) 37,850,719 Adjustment for correction of error - - - - 2,476 2,476 Balance at 1 July 2021 - restated 80,290,062 464,000 (453,320) 1,753,886 (44,201,433) 37,853,195 Loss after income tax benefit for the year (restated) - - - - (25,014,055) (25,014,055) Other comprehensive income for the year, net of tax - - 34,615 - - 34,615 Total comprehensive income for the year - - 34,615 - (25,014,055) (24,979,440) Transactions with owners in their capacity as owners: Shares issued (note 20) 4,202,222 - - - - 4,202,222 Share issue costs (note 20) (492,735) - - - - (492,735) Immaterial reclassification - - (433,333) - 433,333 - Issue of shares on exercise of options 16,700 - - (5,622) 5,622 16,700 Cancellation of convertible note 464,000 (464,000) - - - - Share based payments (note 35) - - - 1,674,581 - 1,674,581 Expired options - - - (159,142) 159,142 - Balance at 30 June 2022 restated 84,480,249 - (852,038) 3,263,703 (68,617,391) 18,274,523 The above statement of changes in equity should be read in conjunction with the accompanying notes FINANCIAL REPORT

RkJQdWJsaXNoZXIy MjE2NDg3